Novartis to sell 70.68% stake in Novartis India for 14.46 billion rupees
Novartis agreed to sell its 70.68% stake in Novartis India Ltd. for 14.46 billion rupees. The buyers also launched a 26% open offer at 860.84 rupees per share.
Methergine
DrugAlso known as: Methergine
Drug Profile
Methergine (methylergonovine maleate) is an ergot alkaloid uterotonic used after delivery of the placenta to prevent and control postpartum hemorrhage from uterine atony or subinvolution. It is available in oral and injectable formulations with contraindications including pregnancy and hypertension. It is an established prescription obstetric medicine.
- Drug Class
- Semi-synthetic ergot alkaloid uterotonic
- Approval Status
- Marketed human prescription drug
- Methergine
- \methylergonovine maleate\
- \Routine management after delivery of the placenta\
- \Postpartum uterine atony and hemorrhage\
- Subinvolution
Related News
Novartis Exits Indian Listed Unit With $159 Million Stake Sale
Novartis AG sells its entire 70.68% stake in Novartis India Ltd. for $159 million to a consortium of investors, concluding a two-year strategic review while maintaining operations through its wholly-owned Indian subsidiary.